117296-93-2

Basic information

• Product Name: 1-[2-(chloromethyl)phenyl]-1H-imidazole
• Synonyms: 1-[2-(chloromethyl)phenyl]-1H-imidazole
• CAS NO: 117296-93-2
• Molecular Formula: C₁₀H₉ClN₂
• Molecular Weight: 192.64486
• Mol File: 117296-93-2.mol
• Article Data: 1

Chemical Properties

• Boiling Point: 354.6±25.0 °C(Predicted)
• Appearance: /
• Density: 1.19±0.1 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: 5.33±0.10(Predicted)
• CAS DataBase Reference: 1-[2-(chloromethyl)phenyl]-1H-imidazole(CAS DataBase Reference)
• NIST Chemistry Reference: 1-[2-(chloromethyl)phenyl]-1H-imidazole(117296-93-2)
• EPA Substance Registry System: 1-[2-(chloromethyl)phenyl]-1H-imidazole(117296-93-2)

Safety Data

• Hazardous Substances Data: 117296-93-2(Hazardous Substances Data)

Usage

General Description

1-[2-(chloromethyl)phenyl]-1H-imidazole, also known as Clotrimazole, is an antifungal medication often used to treat infections caused by fungus, particularly in the skin or mucous membranes. It works by inhibiting the growth of fungi and is commonly found in topical creams, powders, and sprays. Clotrimazole is also effective in treating vaginal yeast infections and has been used for over 50 years in various formulations. Additionally, it has a relatively low risk of side effects and is generally well-tolerated by patients. However, it is important to consult with a healthcare professional before using Clotrimazole to ensure it is the appropriate treatment for the specific condition.

Upstream product

• 246046-82-2 2-Imidazol-1-yl-benzoic acid methyl ester 
• 394-35-4 methyl 2-fluorobenzoate 
• 25373-56-2 (2-imidazol-1-yl-phenyl)-methanol 

Downstream Products

• 117323-65-6 2-[2-(2-Imidazol-1-yl-benzylsulfanyl)-imidazol-1-yl]-pyridine 

Relevant articles and documents

2-[(2-Aminobenzyl)sulfinyl]-1-(2-pyridyl)-1,4,5,6- tetrahydrocyclopent[d]imidazoles as a novel class of gastric H+/K+-ATPase inhibitors

Substituted 2-sulfinylimidazoles were synthesized and investigated as potential inhibitors of gastric H+/K+-ATPase. The 4,5-unsubstituted imidazole series 6-11 and the 1,4,5,6-tetrahydrocyclopent[d]imidazole series 12 were found to be potent inhibitors of the acid secretory enzyme H+/K+- ATPase. Structure-activity relationships indicate that the substitution of 2- pyridyl groups at the 1-position of the imidazole moiety combined with (2- aminobenzyl)sulfinyl groups at the 2-position leads to highly active compounds with a favorable chemical stability. Other substitution patterns in the imidazole moiety result in reducing biological activities. 2-[(2- Aminobenzyl)sulfinyl]-1-[2-(3-methylpyridyl)]-1,4,5,6- tetrahydrocyclopent[d]imidazole (12h, T-776) was selected for further development as a potential clinical candidate. Extensive study on the acid degradation of 12h indicates a mechanism of action different from that of omeprazole, the first H+/K+-ATPase inhibitor introduced to the market.